TiumBio Co., Ltd. (KOSDAQ:321550)

TiumBio Statistics

Total Valuation

TiumBio has a market cap or net worth of KRW 170.20 billion. The enterprise value is 167.43 billion.

Market Cap	170.20B
Enterprise Value	167.43B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

TiumBio has 27.14 million shares outstanding. The number of shares has increased by 11.99% in one year.

Current Share Class	27.14M
Shares Outstanding	27.14M
Shares Change (YoY)	+11.99%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	36.09%
Owned by Institutions (%)	0.04%
Float	17.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.21
PB Ratio	3.14
P/TBV Ratio	4.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.96
EV / Sales	22.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.38

Financial Position

The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.68.

Current Ratio	2.16
Quick Ratio	1.88
Debt / Equity	0.68
Debt / EBITDA	n/a
Debt / FCF	-2.74
Interest Coverage	-4.08

Financial Efficiency

Return on equity (ROE) is -21.68% and return on invested capital (ROIC) is -12.79%.

Return on Equity (ROE)	-21.68%
Return on Assets (ROA)	-11.04%
Return on Invested Capital (ROIC)	-12.79%
Return on Capital Employed (ROCE)	-22.77%
Revenue Per Employee	107.85M
Profits Per Employee	-154.27M
Employee Count	68
Asset Turnover	0.07
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.73% in the last 52 weeks. The beta is 0.55, so TiumBio's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	+5.73%
50-Day Moving Average	5,615.30
200-Day Moving Average	4,750.00
Relative Strength Index (RSI)	57.88
Average Volume (20 Days)	196,002

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TiumBio had revenue of KRW 7.33 billion and -10.49 billion in losses. Loss per share was -397.77.

Revenue	7.33B
Gross Profit	6.68B
Operating Income	-18.44B
Pretax Income	-12.55B
Net Income	-10.49B
EBITDA	-14.79B
EBIT	-18.44B
Loss Per Share	-397.77

Balance Sheet

The company has 51.25 billion in cash and 37.06 billion in debt, giving a net cash position of 14.19 billion or 522.62 per share.

Cash & Cash Equivalents	51.25B
Total Debt	37.06B
Net Cash	14.19B
Net Cash Per Share	522.62
Equity (Book Value)	54.15B
Book Value Per Share	1,581.34
Working Capital	32.55B

Cash Flow

In the last 12 months, operating cash flow was -13.41 billion and capital expenditures -118.65 million, giving a free cash flow of -13.53 billion.

Operating Cash Flow	-13.41B
Capital Expenditures	-118.65M
Free Cash Flow	-13.53B
FCF Per Share	-498.31

Margins

Gross margin is 91.10%, with operating and profit margins of -251.41% and -143.04%.

Gross Margin	91.10%
Operating Margin	-251.41%
Pretax Margin	-171.18%
Profit Margin	-143.04%
EBITDA Margin	-201.63%
EBIT Margin	-251.41%
FCF Margin	n/a

Dividends & Yields

TiumBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.99%
Shareholder Yield	-11.99%
Earnings Yield	-6.16%
FCF Yield	-7.95%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TiumBio has an Altman Z-Score of 0.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.96
Piotroski F-Score	2